Lingua: Inglese
Editore: Chapman and Hall/CRC Press, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Da: Salish Sea Books, Bellingham, WA, U.S.A.
Condizione: Very Good. Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam padding; Medium Format (8.5" - 9.75" tall); Dark blue and aqua covers with title in white lettering; 2013, Chapman and Hall/CRC Press; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
Hardcover. Condizione: Very Good. 1439867941 Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam padding; Medium Format (8.5" - 9.75" tall); Aqua and blue covers with title in white lettering; 2013, Chapman and Hall/CRC; 220 pages; "Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)," by Andreas Sashegyi, et al.
hardcover. Condizione: New. Brand New Book.
Da: Studibuch, Stuttgart, Germania
EUR 24,50
Quantità: 1 disponibili
Aggiungi al carrellohardcover. Condizione: Sehr gut. 220 Seiten; 9781439867945.2 Gewicht in Gramm: 1.
Condizione: As New. Unread book in perfect condition.
Condizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 119,46
Quantità: 10 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 124,94
Quantità: 10 disponibili
Aggiungi al carrelloCondizione: New.
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
EUR 124,96
Quantità: 1 disponibili
Aggiungi al carrelloHardback. Condizione: New. New copy - Usually dispatched within 4 working days.
Condizione: New. pp. 220.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 142,87
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New. pp. 220.
Da: moluna, Greven, Germania
EUR 118,51
Quantità: Più di 20 disponibili
Aggiungi al carrelloGebunden. Condizione: New.
Lingua: Inglese
Editore: Taylor & Francis Inc Nov 2013, 2013
ISBN 10: 1439867941 ISBN 13: 9781439867945
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 146,37
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Neuware - Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule's journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies.The book also focuses on a molecule's entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety. Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
Da: Majestic Books, Hounslow, Regno Unito
EUR 125,55
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New. pp. 220 A 7 fig, 4-page color insert will appear of Figs. 5.10-5.16. follows page 96 This item is printed on demand.